Archive: February 16 2021
Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Prof Robin Foà comments on NEJM paper “Dasatinib - Blinatumomab for Ph+ ALL in A...
Listen to Prof. Robin Foà commenting on the rationale and the results of a highly relevant paper published on the New England Journal of Medicine, and reporting an innovative “chemo-free” approach for Ph+ ALL patients. Robin Foà, first author of the paper, highlights the main findings and scientific implications of a clinical trial involving 63 newly diagnosed adult patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).